Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Ascentage Pharma Group International

Healthcare US ASPHF

5.04USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

5.055.05
LowHigh

52 Week Range

5.8310.65
LowHigh

Fundamentals

  • Previous Close 5.04
  • Market Cap3165.77M
  • Volume100
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1132.25203M
  • Revenue TTM574.12M
  • Revenue Per Share TTM1.61
  • Gross Profit TTM 525.18M
  • Diluted EPS TTM-0.53

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -1204.14976M -395.25500M -932.86200M -887.17200M -832.24900M
Minority interest - 0.25M 0.07M - -
Net income -1210.69829M -405.43300M -925.63700M -882.92400M -782.42400M
Selling general administrative - 187.12M 181.08M 170.59M 62.26M
Selling and marketing expenses - 196.00M 195.39M 157.42M 47.75M
Gross profit 427.38M 951.57M 191.44M 187.71M 24.58M
Reconciled depreciation - 93.17M 93.19M 62.91M 13.37M
Ebit -1180.90548M -330.80000M -836.80500M -846.12400M -876.22800M
Ebitda -1096.65718M -237.63100M -743.61000M -783.20900M -847.90200M
Depreciation and amortization 84.25M 93.17M 93.19M 62.91M 28.33M
Non operating income net other - - - - -
Operating income -1180.90548M -369.73000M -872.63600M -846.12400M -876.22800M
Other operating expenses 1740.21M 1350.38M 1094.62M 1059.52M 897.75M
Interest expense 52.67M 64.45M 96.06M 52.78M 16.73M
Tax provision - 10.43M -7.15000M -4.24800M -49.82500M
Interest income - 37.84M 32.41M 9.73M 7.11M
Net interest income - -26.61500M -63.64800M -43.05800M -9.62500M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 6.76M 10.43M -7.15000M -4.24800M -49.82500M
Total revenue 559.30M 980.65M 221.98M 209.71M 27.91M
Total operating expenses 1608.29M 1321.30M 1064.08M 1037.52M 894.42M
Cost of revenue 131.92M 29.09M 30.54M 22.00M 3.33M
Total other income expense net -23.24428M -25.52500M -60.22600M -41.04800M 43.98M
Discontinued operations - - - - -
Net income from continuing ops - -405.68000M -925.71200M -882.92400M -782.42400M
Net income applicable to common shares - - - - -782.42400M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3965.58M 2617.81M 2500.39M 2830.26M 2940.06M
Intangible assets 65.97M 76.00M 85.45M 84.30M 90.27M
Earning assets - - - - -
Other current assets 192.63M 131.91M 81.73M - 83.56M
Total liab 2630.69M 2343.65M 2429.76M 2421.60M 1705.32M
Total stockholder equity 1325.13M 264.19M 60.42M 408.66M 1234.74M
Deferred long term liab - - - - -
Other current liab 276.81M 231.87M 236.94M 267.21M 240.80M
Common stock 0.26M 0.21M 0.20M 0.18M 0.18M
Capital stock - 0.21M 0.20M 0.18M 0.18M
Retained earnings - -5770.55500M -5365.12200M -4439.48500M -3556.56100M
Other liab - - - - 309.38M
Good will 24.71M 24.69M 24.69M 24.69M 24.69M
Other assets - - - - 97.46M
Cash 2471.33M 1236.58M 1069.30M 1475.64M 1706.89M
Cash and equivalents - - - - -
Total current liabilities 1644.20M 1166.61M 934.17M 881.15M 361.11M
Current deferred revenue 37.50M 54.09M - - -
Net debt -490.61370M 431.92M 726.30M 317.09M -622.59600M
Short term debt 1223.10M 779.06M 616.40M 518.38M 49.45M
Short long term debt - 769.62M 606.65M 510.31M 39.80M
Short long term debt total 1980.72M 1668.50M 1795.60M 1792.73M 1084.29M
Other stockholder equity -2.96249M 6545.12M 5929.80M 4847.96M 1234.56M
Property plant equipment - - - - 844.37M
Total current assets 2945.66M 1474.16M 1344.18M 1636.49M 1885.28M
Long term investments - 33.86M 18.95M - -
Net tangible assets - - - - 1149.63M
Short term investments - - 31.09M - -
Net receivables 253.07M 99.07M 145.89M 54.36M 76.45M
Long term debt - 868.64M 1166.27M 1265.20M 1026.59M
Inventory 28.63M 6.60M 16.17M 9.45M 3.93M
Accounts payable 106.79M 91.97M 72.44M 95.56M 70.86M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1327.84M -510.58600M -504.46100M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 30.74M 59.00M 69.73M 380.46M 63.73M
Deferred long term asset charges - - - - -
Non current assets total 1019.92M 1143.65M 1156.21M 1193.77M 1054.78M
Capital lease obligations - 30.23M 22.68M 17.22M 17.90M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -362.03500M 21.92M -384.61200M -10.22800M 144.11M
Change to liabilities - - - 274.89M 15.38M
Total cashflows from investing activities -362.03500M 21.92M - -466.52200M -107.36700M
Net borrowings -145.34000M -13.35700M - 539.50M 425.13M
Total cash from financing activities 314.77M 368.75M 619.27M 1781.39M 1040.00M
Change to operating activities - - - -17.01300M -55.25100M
Net income -395.25500M -932.86200M -887.17200M -832.24900M -675.44800M
Change in cash -144.94800M -307.59100M -361.24700M 686.91M 280.99M
Begin period cash flow 1038.05M 1345.64M 1706.89M 1019.98M 738.99M
End period cash flow 893.10M 1038.05M 1345.64M 1706.89M 1019.98M
Total cash from operating activities -111.35700M -726.07700M -653.91500M -604.67900M -609.95600M
Issuance of capital stock 533.94M 470.09M 0.02M 1300.64M 634.22M
Depreciation 93.17M 93.19M 62.91M 28.33M 27.42M
Other cashflows from investing activities -312.23000M 88.03M - - -
Dividends paid 0.00000M 0.00000M - - -
Change to inventory 9.57M -6.71900M -5.51800M -3.93000M -3.93000M
Change to account receivables 62.75M -91.53700M - -53.96800M -53.96800M
Sale purchase of stock 0.00000M -5.92300M -26.77600M -25.87400M -
Other cashflows from financing activities -73.83300M -82.05000M 700.53M 557.77M 500.79M
Change to netincome - - - -40.23400M 87.96M
Capital expenditures 24.29M 56.84M 236.96M 436.63M 251.48M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 110.97M -9.14600M 104.41M 189.65M -47.73200M
Stock based compensation 20.92M 31.50M 22.11M 46.97M 74.03M
Other non cash items 58.84M 91.23M 43.82M -37.38000M 11.78M
Free cash flow -135.64600M -782.92100M -890.87800M -1041.30800M -861.43200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ASPHF
Ascentage Pharma Group International		 - -% 5.04 - - 5.51 32.72 41.25 -0.8161
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Ascentage Pharma Group International

Suzhou Industrial Park, Suzhou, China, 215000

Key Executives

Name Title Year Born
Dr. Dajun Yang Co-Founder, Chairman & CEO 1963
Dr. Shaomeng Wang Ph.D. Co-Founder, Chairman of Scientific Advisory Board & Non-Exec. Director 1964
Mr. Thomas Knapp Sr. VP & Gen. Counsel 1952
Dr. Yifan Zhai M.D., Ph.D. Chief Medical Officer 1963
Douglas Dong Fang Sr. VP of Preclinical Devel. NA
Jianfeng Wen Sr. VP of Pharmaceutical Science NA
Mr. Raymond Kmetz Chief Bus. Officer 1958
Mr. Gang Zhu Chief Commercial Officer 1960
Mr. Cheung Ki Wong A.C.I.S., A.C.S., ACIS, ACS, FCPA Company Sec. 1983
Dr. Dajun Yang M.D., Ph.D. Co-Founder, Chairman & CEO 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.